Achilles Therapeutics Doses First Patient with Higher-Dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 Checkpoint Inhibitor) in Metastatic Malignant Melanoma

Achilles Therapeutics plc announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the company’s higher-dose VELOS™ Process II’ in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung cancer.